DTIC

DRUG8 trials

Sponsors

M.D. Anderson Cancer Center, University of Cologne, AmpliMed Corporation, Novartis Pharmaceuticals, Philogen S.p.A.

Conditions

Hodgkin DiseaseHodgkin LymphomaHodgkin´s LymphomaMalignant MelanomaMelanomaMetastatic Melanoma Stage IV

Phase 1

Safety and Efficacy Trial of Imexon Plus DTIC in Advanced Malignant Melanoma

CompletedNCT00327600

AmpliMed CorporationMalignant Melanoma

Start: 2005-07-31End: 2007-12-31Updated: 2010-09-15

Adriamycin, Vinblastine, DTIC and Revlimid in Elderly Hodgkin Lymphoma Patients

CompletedNCT01056679

University of CologneHodgkin Lymphoma

Start: 2010-04-30End: 2016-02-29Target: 30Updated: 2018-03-22

A Phase I/II Dose Escalation Study of the Tumor-targeting Human L19-IL2 Monoclonal Antibody-cytokine Fusion Protein in Combination With Dacarbazine for Patients With Metastatic Melanoma

Philogen S.p.A.Metastatic Melanoma Stage IV

Start: 2013-07-31End: 2022-06-30Target: 96Updated: 2022-04-14

Phase 2

A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation

CompletedNCT01028222

Novartis PharmaceuticalsMelanoma

Start: 2010-06-30End: 2014-12-31Updated: 2015-12-30

Pediatric Classical Hodgkin Lymphoma Consortium Study: cHOD17

Active, not recruitingNCT03755804

St. Jude Children's Research HospitalHodgkin Lymphoma

Start: 2018-12-12End: 2028-07-01Updated: 2026-06-17

Phase 3

Prophylactic Use of Filgrastim SD/01 in Patients With Hodgkin's Disease Receiving ABVD Chemotherapy

CompletedNCT00038558

M.D. Anderson Cancer CenterHodgkin Disease

Start: 2001-11-30End: 2005-03-31Updated: 2018-10-31

HD10 for Early Stages

CompletedNCT00265018

University of CologneHodgkin´s Lymphoma

Start: 1998-05-31Updated: 2011-07-29

HD11 for Intermediate Stages

CompletedNCT00264953

University of CologneHodgkin´s Lymphoma

Start: 1998-05-31Updated: 2011-08-04

Related Papers

Metabolic-only response assessment for omission of residual node radiation therapy (RNRT) for patients with classical Hodgkin lymphoma (cHL) and impact on event free (EFS) and overall survival (OS): A report from the Pediatric Hodgkin Consortium’s phase 2 study cHOD17 (NCT03755804).

Journal of Clinical Oncology2025-05-28

Efficacy and safety of nilotinib in patients with KIT-mutated metastatic or inoperable melanoma: final results from the global, single-arm, phase II TEAM trial.

2017-06-01121 citations

Risk factors and a prognostic score for survival after autologous stem-cell transplantation for relapsed or refractory Hodgkin lymphoma.

2017-06-0158 citations

Bleomycin in older early-stage favorable Hodgkin lymphoma patients: analysis of the German Hodgkin Study Group (GHSG) HD10 and HD13 trials

Blood2016-02-02112 citations

An individual patient-data comparison of combined modality therapy and ABVD alone for patients with limited-stage Hodgkin lymphoma.

2013-10-1131 citations

Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma.

2010-08-01583 citations